Stay updated with the Dr Reddys Stock Liveblog, your one-stop destination for real-time information and analysis of a leading ...

Indian generic injectables maker Gland Pharma reported a 7% rise in third-quarter profit on Monday, as lower expenses helped mitigate the impact from production issues at its French unit ...

New Delhi: Pharmaceutical major Dr Reddy's has got approval from the Subject Expert Committee (SEC) functional under the ...

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Dr. Reddy’s Laboratories has received an order directing the company to pay more than ₹184 crore penalty under the CGST Act 2017. The authority has passed the order on the contention that the company ...

Union budget 2025-26 takes strong steps toward nation-building through structural reforms such as investment in technology and infrastructure, simplification of tax slabs and duties, among ...

Dr Reddy's Laboratories Chairman Satish Reddy hails Union Budget 2025-26 for its focus on nation-building through structural reforms, including investment in technology, infrastructure, and healthcare ...

The Union Budget 2025-26 emphasizes nation-building through structural reforms in technology and infrastructure. It focuses on healthcare improvements, private-sector-driven research, digital ...

Dr. Reddy's Laboratories Ltd. closed 14.27% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Asian equities traded in the US as American depositary receipts were sharply higher Thursday morning, rising 1.61% to 2,174.43 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...